Human bikunin
AssigneeBayer Aktiengesellschaft
InventorsPaul P. Tamburini, Gary Davis, Katherine A. Delaria, Christopher W. Marlor, Daniel K. Muller
Life of this patent
Estimating the term…
Abstract
The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof.
Claims11
A substantially purified protein, having serine protease inhibitory activity, selected from the group of proteins consisting of materials each of which comprises one of the following amino acid sequences, the amino acids of said sequences being numbered in accordance with the amino acid sequence of native human placental bikunin shown in FIG. 4F in which the N-terminal residue generated by removal of signal peptide is designated as residue 1:
- 46 ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 (SEQ ID NO:52) YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRGFRQQ ENPPLPLGSK;
- MAQLCGL RRSRAFLALL GSLLLSGVLA −1 (SEQ ID NO.:49) ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVFSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS SGDDKEQLVK NTYVL. 225 ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 (SEQ ID NO.:71) YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS SGDDKEQLVK NTYVL, 225 AGSFLAWL GSLLLSGVLA −1 (SEQ ID NO.. 2) ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGAVS, 179 MLR AEADGVSRLL GSLLLSGVLA −1 (SEQ ID NO.:45) ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS SGDDKEQLVK NTYVL, 225 MAQLCGL RRSRAFLALL GSLLLSGVLA −1 (SEQ ID NO.:47) ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS FGD, 213 ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 (SEQ ID NO.:70) YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 ACMLRCFRQQ ENPPLPLGSK VVVLAGLFVM VLILFLGASM VYLIRVARRN 200 QERALRTVWS FGD;
- 213 IHDF CLVSKVVGRC RASMFRWWYN VTDGSCQLFV YGGCDGNSNN 50 (SEQ ID NO.:4) YLTKEECLKK CATV;
- 64 CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 (SEQ ID NO.:5) YLTKEECLKK C;
- 61 YEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 150 (SEQ ID NO.:6) ACMLRCFRQ;
- 159 CTANAVTGPC RASFPRWYFD VERNSCNNFI YGGCRGNKNS YRSEE 150 (SEQ ID NO.:7) ACMLRC;
- 156 IHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 (SEQ ID NO.:3) YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 75 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 125 ACMLRCFRQ;
- 159 CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 (SEQ ID NO.:50) YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 100 NYEEYCTANA VTGPGRASFP RWYFDVERNS CNNFTYGGCR GNKNSYRSEE 150 ACMLRC;
- 156 ADRERSIHDF CLVSKVVGRC RASMFRWWYN VTDGSCQLEV YGGCDGNSNN 25 (SEQ ID NO.:1) YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DSEDHSSDMF 75 NYEEYCTANA VTGPCRASFP RWYFDVERNS CNNFIYGGCR GNKNSYRSEE 125 ACMLRCFRQQ ENPPLPLGSK VVVLAGAVS;
- 179 and ADRERSIHDF CLVSKVVGRC RASMPRWWYN VTDGSCQLFV YGGCDGNSNN 50 (SEQ ID NO.:8) YLTKEECLKK CATVTENATG DLATSRNAAD SSVPSAPRRQ DS. 92
Dependencies are inferred from the claim text.